Yes icliusig will bring in some cash but more new trials will start as well incrasing the burn rate. 600 people were taking iclusig with second line label and that number dropped to 200 something with third line label. With the recent withdrawl and FDAs bs on vascular issue iclusig will be a hard drug to sell.
Market Data 
Markets 
AI
